Subscribe to RSS
DOI: 10.1055/s-0044-1786537
Ablation of Primary and Recurrent Thyroid Cancer: Current and Future Perspectives
Abstract
Thyroid cancer is the most common endocrine malignancy, and its incidence is increasing, driven in part by the advent of ultrasound, and subsequent increased detection of small, early thyroid cancers. Yet even for small tumors, thyroidectomy with lymph node dissection remains standard of care. Specific to well-differentiated thyroid cancer, surgery has come under scrutiny as a possible overtreatment, in light of stable and favorable survival rates even as guidelines have allowed fewer radical resections and lymph node dissections over time. Moreover, thyroid cancer unfortunately has a known recurrence rate regardless of therapy, and surgical re-intervention for local structural recurrence is eventually limited by scar. Radioactive iodine therapy, another accepted treatment, is minimally invasive but can only treat patients with iodine-avid tumors. For all of these reasons, image-guided thermal ablation has emerged as a valuable complementary tool as a thyroid-sparing, parathyroid-sparing, voice-sparing, repeatable, minimally invasive outpatient focal therapy for both primary and recurrent well-differentiated thyroid cancers. However, the data are still evolving, and this represents a new patient cohort for some interventional radiologists. Therefore, the goal of this review is to discuss the technique and evidence for ablation of patients with thyroid cancer.
Publication History
Article published online:
10 July 2024
© 2024. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Seib CD, Sosa JA. Evolving understanding of the epidemiology of thyroid cancer. Endocrinol Metab Clin North Am 2019; 48 (01) 23-35
- 2 Chatchomchuan W, Thewjitcharoen Y, Karndumri K. et al. Recurrence factors and characteristic trends of papillary thyroid cancer over three decades. Int J Endocrinol 2021; 2021: 9989757
- 3 Chen J, Cao J, Qiu F, Huang P. The efficacy and the safety of ultrasound-guided ablation therapy for treating papillary thyroid microcarcinoma. J Cancer 2019; 10 (21) 5272-5282
- 4 Feng J, Jiang Y, Feng Y. Latest evidence of microwave ablation for papillary thyroid microcarcinoma compared with surgery: a systematic review and meta-analysis. Front Oncol 2023; 13: 1088265
- 5 Shin JH, Baek JH, Ha EJ, Lee JH. Radiofrequency ablation of thyroid nodules: basic principles and clinical application. Int J Endocrinol 2012; 2012: 919650
- 6 Mauri G, Hegedüs L, Bandula S. et al. European Thyroid Association and Cardiovascular and Interventional Radiological Society of Europe 2021 Clinical Practice guideline for the use of minimally invasive treatments in malignant thyroid lesions. Eur Thyroid J 2021; 10 (03) 185-197
- 7 Ding M, Tang X, Cui D. et al. Clinical outcomes of ultrasound-guided radiofrequency ablation for the treatment of primary papillary thyroid microcarcinoma. Clin Radiol 2019; 74 (09) 712-717
- 8 Han ZY, Dou JP, Zheng L. et al. Safety and efficacy of microwave ablation for the treatment of low-risk papillary thyroid microcarcinoma: a prospective multicenter study. Eur Radiol 2023; 33 (11) 7942-7951
- 9 Min Y, Wang X, Chen H, Chen J, Xiang K, Yin G. Thermal ablation for papillary thyroid microcarcinoma: how far we have come?. Cancer Manag Res 2020; 12: 13369-13379
- 10 Xu B, Zhou NM, Cao WT, Gu SY. Comparative study on operative trauma between microwave ablation and surgical treatment for papillary thyroid microcarcinoma. World J Clin Cases 2018; 6 (15) 936-943
- 11 van Dijk SPJ, Coerts HI, Gunput STG. et al. Assessment of radiofrequency ablation for papillary microcarcinoma of the thyroid: a systematic review and meta-analysis. JAMA Otolaryngol Head Neck Surg 2022; 148 (04) 317-325
- 12 Zhang M, Tufano RP, Russell JO. et al. Ultrasound-guided radiofrequency ablation versus surgery for low-risk papillary thyroid microcarcinoma: results of over 5 years' follow-up. Thyroid 2020; 30 (03) 408-417
- 13 Cavalheiro BG, Shah JP, Randolph GW. et al. Management of recurrent well-differentiated thyroid carcinoma in the neck: a comprehensive review. Cancers (Basel) 2023; 15 (03) 923
- 14 Hughes DT, Laird AM, Miller BS, Gauger PG, Doherty GM. Reoperative lymph node dissection for recurrent papillary thyroid cancer and effect on serum thyroglobulin. Ann Surg Oncol 2012; 19 (09) 2951-2957
- 15 Pacini F, Cetani F, Miccoli P. et al. Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine. World J Surg 1994; 18 (04) 600-604
- 16 Young S, Chen T, Golzarian J, Sanghvi T. Ablation of cervical lymph nodes in patients with thyroid cancer: a comparison between cryoablation and percutaneous ethanol injection. J Vasc Interv Radiol 2023; 34 (05) 777-781.e1
- 17 Sag AA, Perkins JM, Kazaure HS. et al. Salvage cryoablation for local recurrences of thyroid cancer inseparable from the trachea and neurovascular structures. J Vasc Interv Radiol 2023; 34 (01) 54-62
- 18 Shin JE, Baek JH, Lee JH. Radiofrequency and ethanol ablation for the treatment of recurrent thyroid cancers: current status and challenges. Curr Opin Oncol 2013; 25 (01) 14-19
- 19 Heilo A, Sigstad E, Fagerlid KH. et al. Efficacy of ultrasound-guided percutaneous ethanol injection treatment in patients with a limited number of metastatic cervical lymph nodes from papillary thyroid carcinoma. J Clin Endocrinol Metab 2011; 96 (09) 2750-2755
- 20 Tofé S, Argüelles I, Álvarez C. et al. Ultrasound-guided ethanol percutaneous ablation versus rescue surgery in patients with locoregional recurrence of papillary thyroid cancer. Clin Exp Otorhinolaryngol 2023; 16 (04) 380-387
- 21 Frich PS, Sigstad E, Berstad AE. et al. Long-term efficacy of ethanol ablation as treatment of metastatic lymph nodes from papillary thyroid carcinoma. J Clin Endocrinol Metab 2022; 107 (05) e2141-e2147
- 22 Tofé S, Argüelles I, Serra G, García H, Barcelo A, Pereg V. Ultrasound-guided percutaneous ethanol ablation for the management of recurrent thyroid cancer: evaluation of efficacy and impact on disease course. Int J Thyroid 2020; 13 (02) 128-141
- 23 Fontenot TE, Deniwar A, Bhatia P, Al-Qurayshi Z, Randolph GW, Kandil E. Percutaneous ethanol injection vs reoperation for locally recurrent papillary thyroid cancer: a systematic review and pooled analysis. JAMA Otolaryngol Head Neck Surg 2015; 141 (06) 512-518
- 24 Suh CH, Baek JH, Choi YJ, Lee JH. Efficacy and safety of radiofrequency and ethanol ablation for treating locally recurrent thyroid cancer: a systematic review and meta-analysis. Thyroid 2016; 26 (03) 420-428
- 25 Guenette JP, Monchik JM, Dupuy DE. Image-guided ablation of postsurgical locoregional recurrence of biopsy-proven well-differentiated thyroid carcinoma. J Vasc Interv Radiol 2013; 24 (05) 672-679
- 26 Kim HJ, Cho SJ, Baek JH. Comparison of thermal ablation and surgery for low-risk papillary thyroid microcarcinoma: a systematic review and meta-analysis. Korean J Radiol 2021; 22 (10) 1730-1741
- 27 Lewis BD, Hay ID, Charboneau JW, McIver B, Reading CC, Goellner JR. Percutaneous ethanol injection for treatment of cervical lymph node metastases in patients with papillary thyroid carcinoma. AJR Am J Roentgenol 2002; 178 (03) 699-704
- 28 Paz-Fumagalli R, Li X, Smallridge RC. Ethanol ablation of neck metastases from differentiated thyroid carcinoma. Semin Intervent Radiol 2019; 36 (05) 381-385
- 29 Tufano RP, Pace-Asciak P, Russell JO. et al. Update of radiofrequency ablation for treating benign and malignant thyroid nodules. The future is now. Front Endocrinol (Lausanne) 2021; 12: 698689
- 30 Jensen CB, Pitt SC. Patient perception of receiving a thyroid cancer diagnosis. Curr Opin Endocrinol Diabetes Obes 2021; 28 (05) 533-539
- 31 Miyauchi A, Kudo T, Ito Y. et al. Estimation of the lifetime probability of disease progression of papillary microcarcinoma of the thyroid during active surveillance. Surgery 2018; 163 (01) 48-52
- 32 Hegedüs L, Miyauchi A, Tuttle RM. Nonsurgical thermal ablation of thyroid nodules: not if, but why, when, and how?. Thyroid 2020; 30 (12) 1691-1694